US 12,136,473 B2
Methods of predicting disorder progression for control arms within an experimental trial
Greg Zaharchuk, Stanford, CA (US)
Assigned to The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Filed by The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Filed on Jun. 3, 2020, as Appl. No. 16/892,158.
Claims priority of provisional application 62/856,653, filed on Jun. 3, 2019.
Prior Publication US 2020/0381096 A1, Dec. 3, 2020
Int. Cl. G16H 10/20 (2018.01); G06F 18/21 (2023.01); G06F 18/25 (2023.01); G06N 3/088 (2023.01); G06N 20/00 (2019.01); G06V 10/764 (2022.01); G06V 10/774 (2022.01); G06V 10/776 (2022.01); G06V 10/82 (2022.01); G16H 10/60 (2018.01); G16H 20/10 (2018.01); G16H 20/40 (2018.01); G16H 30/20 (2018.01); G16H 50/30 (2018.01)
CPC G16H 10/20 (2018.01) [G06F 18/217 (2023.01); G06F 18/251 (2023.01); G06N 3/088 (2013.01); G06N 20/00 (2019.01); G06V 10/764 (2022.01); G06V 10/774 (2022.01); G06V 10/776 (2022.01); G06V 10/82 (2022.01); G16H 10/60 (2018.01); G16H 20/10 (2018.01); G16H 20/40 (2018.01); G16H 30/20 (2018.01); G16H 50/30 (2018.01)] 19 Claims
OG exemplary drawing
 
1. A method of assessing the ability of an experimental treatment to ameliorate the medical disorder, comprising:
capturing or having captured a set of one or more baseline biomedical images from each subject of a cohort of subjects, wherein each subject of the cohort has a medical disorder that is shared among the subjects;
for each subject of the cohort, utilizing or having utilized a trained and validated predictive model and the subject's set of baseline biomedical images to predict the progression of the subject's disorder without the experimental treatment, wherein the predicted disorder progression of each subject of the cohort is utilized as a surrogate for a control arm in a clinical experiment;
for each subject of the cohort, and after having captured a set of one or more baseline biomedical images from each subject, administering or having administered the experimental treatment to the subject, wherein ability of the experimental treatment to ameliorate progression of the medical disorder is being assessed by the administration;
for each subject of the cohort, capturing or having captured a set of one or more experimental biomedical images during or at the end of the experimental treatment; and
for each subject of the cohort, assessing the ability of the experimental treatment to ameliorate progression of the medical disorder by comparing the data of the captured experimental biomedical images with the data of the predicted disorder progression;
wherein the data of the captured experimental biomedical images represents the results of the experimental treatment and the data of the predicted disorder progression represents the control arm.